A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary)
- Indications Ebola virus infections; Viral haemorrhagic fevers
- Focus Adverse reactions; Registrational
- Sponsors Janssen Vaccines and Prevention
- 04 Dec 2017 Planned number of patients changed from 5500 to 1417.
- 13 Jan 2017 Planned End Date changed from 1 May 2022 to 1 Apr 2023.
- 15 Jul 2016 Status changed from not yet recruiting to recruiting.